Information Provided By: 
Fly News Breaks for February 5, 2018
CLVS
Feb 5, 2018 | 07:27 EDT
Leerink analyst Michael Schmidt says that Clovis' Rubraca CHMP decision could remove a small overhang in the shares while noting downside is limited. While the analyst thinks it is difficult to predict the outcome of Clovis' Rubraca MAA in the 3rd line ovarian cancer treatment setting, he believes a possible negative outcome should not materially affect Clovis' valuation or his investment thesis on the stock while a positive opinion could remove a small overhang on the stock. He reiterates an Outperform rating and $90 price target on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
